SPEXOTRAS

This brand name is authorized in Austria, Croatia, Estonia, France, Ireland, Italy, Lithuania, Romania.

Active ingredients

The drug SPEXOTRAS contains one active pharmaceutical ingredient (API):

1	Trametinib UNII 33E86K87QN - TRAMETINIB
	Trametinib is a reversible, highly selective, allosteric inhibitor of mitogen-activated extracellular signal regulated kinase 1 (MEK1) and MEK2 activation and kinase activity. In melanoma and other cancers, this pathway is often activated by mutated forms of BRAF which activates MEK. Trametinib inhibits activation of MEK by BRAF and inhibits MEK kinase activity.
	Read more about Trametinib

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
SPEXOTRAS Powder for oral solution	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L01EE01		L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01E Protein kinase inhibitors → L01EE Mitogen-activated protein kinase (MEK) inhibitors
Discover more medicines within L01EE01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	3064867
FR	Base de données publique des médicaments	64421282
IT	Agenzia del Farmaco	051049017
LT	Valstybinė vaistų kontrolės tarnyba	1098663
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W70093001